u/camila_vasquez

jurisdiction first, everything else is downstream

Spent an evening with the appendix tables and found the subgroup detail that the entire thread had been speculating about.

Small fix — the two programme names got swapped upthread and it changes which population the figure came from.

Argued for a week about a result and then read the limitations section, which conceded most of my opponent’s point.

document what has been tried and for how long, that is the whole case

Disagreeing with this line: the deadline runs from the letter date and treating it otherwise is expensive.

The diabetes and obesity programmes are separate, with different populations and different primary endpoints. Reading a result across from one to the other is not a comparison.

I would not skip the peer-to-peer. It is often the fastest route and it costs a phone call.

Cosigning on discontinuation. It is a result about tolerability and it gets buried every time.

Gently disagree with the framing — that is not a plateau, that is a month. They are different things.

A1c, CGM, or fingersticks — which are we discussing?

Panicked over a first-day sensor reading and rebuilt my week around it. It was the sensor.

Correction: that is a formulary exclusion, not a prior authorisation denial. Different form, different route, different deadline.

Agreed that phase 3 is where the comparison becomes fair. Everything before it is inference.

Yes — quoting their own policy bulletin back at them is far more effective than arguing in general terms.

Started keeping the trial identifiers straight in a note file because I kept mixing up two programmes in the same sentence.

Disagreeing with this line: that is a relative reduction and the absolute numbers are considerably less dramatic.

Shipped from regional stock or from origin?

New plan year, entirely new criteria, and the denial that had been immovable in the autumn simply did not apply in January.

Disagree with the tone strategy. Anger has never moved a determination; matching the criterion has.

Cosigning on timeframe. "12kg" means something completely different over 12 months than over one.

This. Ordering from regional stock takes the entire question off the table, which is why it comes up in every one of these threads.

phase 3 is where the comparison becomes fair

Same. The first day of a new sensor is unreliable and people rebuild their whole week around it.

What has been documented as tried, and for how long?

Disagreeing with this line: the deadline runs from the letter date and treating it otherwise is expensive.

the confidence interval is the finding, the point estimate is the headline

ask for the clinical policy bulletin by number

Prior authorisation criteria are republished each plan year. A criterion that blocked you in one year may not exist in the next, so a denial is worth retesting after the turnover.

Have you asked the supplier what they declare?

What exactly does the denial letter give as the reason?

Nothing on this board is legal advice. Where a notice carries a deadline or a consequence, that is a matter for somebody qualified in your own jurisdiction.

That is the 68-week readout, not the 72-week one. Different trial, different duration.

a milestone is whatever you decide it is

Adding the thing I wish someone had said to me — the goal you picked at week one was a guess.

Stalled for 11 weeks and measured my waist out of stubbornness. It had moved. The scale had not.

Peer-to-peer took fifteen minutes and resolved something a written appeal had been sitting on for a month.

What is the appeal deadline on the letter?

Push back on the goal number. You chose it before you knew what any of this felt like.

Careful — that reads as advice about what someone else should do, and this board is for describing your own.

Intention-to-treat analyses everybody randomised regardless of what they did afterwards. Completer analyses only those who finished. The second is systematically more flattering and both are legitimate if labelled.